What GLP-1 users should know about the potential risk of a rare type of vision loss — Live Feedhttps://www.live-feeds.com/feed/what-glp-1-users-should-know-about-the-potential-risk-of-a-rare-type-of-vision-lossContinuously updated, source-cited coverage. Patients Sue GLP-1 Manufacturers Over Rare Vision Loss Riskshttps://www.live-feeds.com/feed/what-glp-1-users-should-know-about-the-potential-risk-of-a-rare-type-of-vision-losshttps://www.live-feeds.com/feed/what-glp-1-users-should-know-about-the-potential-risk-of-a-rare-type-of-vision-loss#u81735Wed, 23 Sep 2026 20:15:59 +0000Over 4,000 complaints have been filed against GLP-1 manufacturers, including Eli Lilly and Novo Nordisk, alleging that drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound caused users to lose their vision. Patients report sudden onset blindness, with some describing the experience as lights out. While these cases are described as rare, the volume of legal action suggests a growing concern over the potential link between these weight-loss and diabetes medications and permanent sight impairment. Medical professionals are currently evaluating the risk associated with these specific drug classes